Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

Overview

The prevalence of functional dyspepsia (FD) is estimated to be 15% of the adult population. FD is commonly described as a condition of chronic abdominal discomfort localized to the upper abdomen. Postprandial bloating, pain, nausea, vomiting, belching, and early satiety are common symptoms of the FD patient. FD is defined by >12 weeks of symptoms, which need not be consecutive, within the preceding year consisting of a) persistent or recurrent dyspepsia and b) an absence of organic disease after a gastrointestinal endoscopy or x-ray series. FD is therefore considered a disorder of function because no mucosal pathology is seen in these patients, as in patients with other functional disorders such as irritable bowel syndrome (IBS) and fibromyalgia (FM). There is a remarkable degree of overlap among these three disorders. These 3 disorders share the finding of hypersensitivity and the symptom of postprandial bloating to suggest the possibility of a common origin.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: March 2012

Interventions

  • Drug: Rifaximin
    • rifaximin 550 mg TID PO x 10 days
  • Procedure: Lactulose Breath Test
    • Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
  • Drug: Placebo
    • placebo TID x 10 days

Arms, Groups and Cohorts

  • Active Comparator: Control Participants
  • Active Comparator: FD Participants
  • Placebo Comparator: FD (Placebo) Participants

Clinical Trial Outcome Measures

Primary Measures

  • To compare the pattern of bacterial gas excretion in breath among Veterans with FD vs. controls using LBT
    • Time Frame: every 15 minutes for 180 minutes

Secondary Measures

  • The investigators will determine the relationship between SIBO in FD patients using randomized antibiotic treatment
    • Time Frame: 2 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Must have FD based on the most recent Umbrella criteria of one or more of: a. bothersome postprandial fullness, b. early satiation, c. epigastric pain, d. epigastric burning – No evidence of organic disease (including H. pylori detected at time of endoscopy) that is likely to explain the symptoms – Criteria must be fulfilled for the last 3 months with symptom onset at least 6 months before the diagnosis – The physical exam, routine blood tests including CBC, chemistry panel and liver tests, upper gastrointestinal endoscopy and 24h pH study must be normal Exclusion Criteria:

  • History of IBS,rheumatoid arthritis,H. Pylori infection,lupus,peptic ulcer, cirrhosis,diabetes, HIV or TB – Inflammatory bowel disease – Bowel Resection (including gastric, small bowel or colon; gallbladder surgery or appendectomy are NOT exclusion criteria) – Anti/pro-biotics last 3 months – Previous LBT (Lactulose Breath Test) – Narcotic Dependence – Pregnancy – Control subjects will be excluded if they have symptoms of heartburn, retrosternal chest pain, chronic cough, nausea or regurgitation suggestive of gastroesophageal reflux disease

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Henry C. Lin, MD
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Henry C. Lin, MD, Henry C. Lin, MD – New Mexico VA Healthcare System
  • Overall Official(s)
    • Henry C Lin, MD, Principal Investigator, New Mexico VA Healthcare System

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.